Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has received approval for an additional indication of its proton pump inhibitor Pariet (generic name: rabeprazole sodium) for non-erosive gastroesophageal reflux disease (GERD) in Japan.
Subscribe to our email newsletter
By providing Pariet as a new treatment option for non-erosive GERD in Japan, Eisai seeks to make further contributions to the treatment of patients with acid-related diseases in hope of improving their quality of life.
Eisai said that Pariet inhibits proton pumps during the last phase of stomach acid secretion and has been clinically shown to have a rapid onset of action and a powerful inhibitory effect on acid secretion.
Pariet was launched first in Japan in 1997, and subsequently made available in Europe in 1998, and the US in 1999, where it is marketed under the brand name AcipHex.
Currently approved in more than 90 countries worldwide, Pariet has already been approved for the treatment of non-erosive-GERD in Europe and the US.
In Japan, the drug is indicated for the treatment of gastric ulcers, duodenal ulcers, reflux esophagitis, and as an adjunctive treatment in the eradication of Helicobacter pylori bacteria in gastric and duodenal ulcers.
The clinical value of Pariet in treating patients with acid related diseases has been further enhanced with the approval of non-erosive GERD as an additional indication.